Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Cell"
DOI: 10.1016/j.ccell.2020.04.013
Abstract: Summary Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising therapeutic activities in cancer and autoimmunity, respectively. We previously showed that epitope and isotype interact to deliver optimal agonistic anti-CD40 mAbs. The impact… read more here.
Keywords: antitumor activity; isotype; isotype switching; anti cd40 ... See more keywords
Tumor localized agonistic anti-CD40 therapy and beyond
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1713084
Abstract: The field of anti-CD40 agonistic antibody therapies is still awaiting the breakthrough in the clinic. Anti-CD40 agonistic antibodies should in theory complement anti-PD1/PDL1 therapy as they provide the necessary CD40 stimulation to antigen-presenting cells, thereby… read more here.
Keywords: therapy; anti tumor; anti cd40; tumor ... See more keywords
Addition of Anti-CD40 Monoclonal Antibody to Nonmyeloablative Conditioning With Belatacept Abrogated Allograft Tolerance Despite Induction of Mixed Chimerism
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation"
DOI: 10.1097/tp.0000000000002417
Abstract: Background We recently reported anti-CD40 monoclonal antibody and rapamycin (aCD40/rapa) to be a reliable, nontoxic, immunosuppressive regimen for combined islet and kidney transplantation (CIKTx) in nonhuman primates. In the current study, we attempted to induce… read more here.
Keywords: allograft tolerance; monoclonal antibody; chimerism; mixed chimerism ... See more keywords
Anti‐CD40 antibody 2C10 binds to a conformational epitope at the CD40‐CD154 interface that is conserved among primate species
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Transplantation"
DOI: 10.1111/ajt.15574
Abstract: The antagonistic anti‐CD40 antibody, 2C10, and its recombinant primate derivative, 2C10R4, are potent immunosuppressive antibodies whose utility in allo‐ and xenotransplantation have been demonstrated in nonhuman primate studies. In this study, we defined the 2C10… read more here.
Keywords: cd40 antibody; anti cd40; cd40; 2c10 binding ... See more keywords
Developing a translational murine‐to‐canine pathway for an IL‐2/agonist anti‐CD40 antibody cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Veterinary and Comparative Oncology"
DOI: 10.1111/vco.12813
Abstract: Abstract Human and canine sarcomas are difficult to treat soft tissue malignancies with an urgent need for new improved therapeutic options. Local recurrence rates for humans are between 10%–30%, and 30%–40% develop metastases. Outcomes for… read more here.
Keywords: cd40 antibody; cancer; canine; cd40 ... See more keywords
Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005718
Abstract: Background Agonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as promising immunotherapeutic compounds with impressive antitumor effects in mouse models. However, preclinical and clinical studies faced dose-limiting toxicities mediated by necroinflammatory liver disease. An effective prophylactic… read more here.
Keywords: liver toxicity; liver; anti cd40; antibody ... See more keywords
Abstract 1531: Human anti-CD40 agonistic antibodies with enhanced FcgR engagement activate immune cell and promote anti-tumor efficacy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1531
Abstract: Checkpoint inhibitors represent a major advance in cancer immunotherapy, and combinatorial immunotherapies with secondary drivers of anti-tumor immunity provide beneficial effects for patients that do not show a strong endogenous immune response. CD40 is a… read more here.
Keywords: cell; immune; anti cd40; anti tumor ... See more keywords
Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3287
Abstract: Stimulating innate immunity can potentially enable us to overcome resistance to PD-(L)1 blockade. We previously conducted a phase 1 trial of cabiralizumab (anti-CSF1R) with sotigalimab (CD40 agonistic antibody) and nivolumab. Our purpose was to determine… read more here.
Keywords: csf1r; anti cd40; anti csf1r; anti anti ... See more keywords
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)
Sign Up to like & getrecommendations! Published in 2021 at "JCI Insight"
DOI: 10.1172/jci.insight.142980
Abstract: Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact. We hypothesized that drugs targeting mitosis might affect the tumor microenvironment and sensitize… read more here.
Keywords: glioblastoma; anti cd40; anti; checkpoint ... See more keywords
Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2021.691781
Abstract: Background CD40, a key co-stimulatory molecule expressed on antigen-presenting cells, is genetically associated with a number of autoimmune diseases including Graves’ disease (GD). Therefore, recent therapies targeting CD40 have been developed, including the anti-CD40 monoclonal… read more here.
Keywords: medicine; response; anti cd40; graves disease ... See more keywords
Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.786144
Abstract: CD40 is a potent activating receptor expressed on antigen-presenting cells (APCs) of the immune system. CD40 regulates many aspects of B and T cell immunity via interaction with CD40L expressed on activated T cells. Targeting… read more here.
Keywords: antigen; cd40; cd40 cd40l; anti cd40 ... See more keywords